Invex Therapeutics (ASX:IXC) NonCurrent Deferred Liabilities: A$0.00 Mil (As of Dec. 2025)


What is Invex Therapeutics NonCurrent Deferred Liabilities?

Invex Therapeutics ASX:IXC NonCurrent Deferred Liabilities is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Invex Therapeutics's non-current deferred liabilities for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Invex Therapeutics NonCurrent Deferred Liabilities Related Terms

Invex Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics NonCurrent Deferred Liabilities Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
What does a NonCurrent Deferred Liabilities of A$0.00 Mil mean?
Invex Therapeutics (ASX:IXC) has a NonCurrent Deferred Liabilities of A$0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' NonCurrent Deferred Liabilities too high?
Invex Therapeutics' current NonCurrent Deferred Liabilities is A$0.00 Mil.
How does Invex Therapeutics' NonCurrent Deferred Liabilities compare to VRTX and REGN?
Invex Therapeutics' NonCurrent Deferred Liabilities of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current NonCurrent Deferred Liabilities is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current NonCurrent Deferred Liabilities of A$0.00 Mil. The current NonCurrent Deferred Liabilities is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current NonCurrent Deferred Liabilities is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.